Pharmacogenomics Market By Method 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Pharmacogenomics Market
Pharmacogenomics Market: By Method (Haplotype Analysis, Multivariate Techniques), By Therapeutic Application (Cancer, Oncology, Cardiovascular), By Application (Drug Safety, Tailor Treatments, Drug Discovery) & By Region-Forecast (2017-2022)
Report Code : HCR 0309
Updated Date: 02 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Pharmacogenomics is the science of individualizing the drug, by studying of inherited variations in human genes that affect an individual’s reaction to a particular drug. Pharmacogenomics also determine an individual’s vulnerability to certain diseases. Globally, development of efficient and advance technology, rising demand for personalized drugs, growing incidences of several infectious and non-infectious diseases, rise in the awareness among people regarding pharmacogenomics, and increasing government initiative across the globe, are the prime growth drivers of global pharmacogenomics market. In addition, increase in adoption of pharmacogenomics in emerging economies such as China, India and others, will create new opportunities for global pharmacogenomics market. However, higher cost of the research and development, complex government approval process, and finding the association between a genetic marker and a phenotypic drug response are the key restraints for global pharmacogenomics market.

 Pharmacogenomics Market

Geographically North America dominated global pharmacogenomics market because of rising demand of personalized medicines, high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and number of R&D centres in developing nations such as China, and India in this region. Among all the applications, drug discovery has the highest market share in global pharmacogenomics market.

This report identifies the global pharmacogenomics market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global pharmacogenomics market.

This report segments global pharmacogenomics market on the basis of method, therapeutic application, application, and regional market as follows:
  • Pharmacogenomics Market, By Method: Haplotype Analysis, and Multivariate Techniques
  • Pharmacogenomics Market, By Therapeutic Application: Cancer, Oncology, and Cardiovascular
  • The report has focused study on pharmacogenomics market by basis of application such as: Drug Safety, Tailor Treatments, and Drug Discovery
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

Sample Companies profiled in this Report are:
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Abbott Laboratories, Inc.
  • 10+.
1. Pharmacogenomics Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Pharmacogenomics Market– Market Forces
   4.1. Drivers
      4.1.1. Rising demand for personalized drugs
      4.1.2. Growing incidences of several infectious and non-infectious diseases
   4.2. Restraints
      4.2.1. Higher cost of research and development
      4.2.2. Finding the association between a genetic marker and a phenotypic drug response
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Pharmacogenomics Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Pharmacogenomics Market, By Method
   6.1. Haplotype Analysis
   6.2. Multivariate Techniques
7. Pharmacogenomics Market, By Therapeutic Application
   7.1. Cancer
   7.2. Oncology
   7.3. Cardiovascular
8. Pharmacogenomics Market, By Application
   8.1. Drug Safety
   8.2. Tailor Treatments
   8.3. Drug Discovery
9. Pharmacogenomics Market, By Geography
   9.1. Europe
      9.1.1. Germany
      9.1.2. France
      9.1.3. Italy
      9.1.4. Spain
      9.1.5. Russia
      9.1.6. U.K.
      9.1.7. Rest of Europe
   9.2. Asia Pacific
      9.2.1. China
      9.2.2. India
      9.2.3. Japan
      9.2.4. South Korea
      9.2.5. Rest of Asia-Pacific
   9.3. North America
      9.3.1. U.S.
      9.3.2. Canada
      9.3.3. Mexico
   9.4. Rest of the World (RoW)
      9.4.1. Brazil
      9.4.2. Rest of RoW
10. Pharmacogenomics – Market Entropy
   10.1. Expansion
   10.2. Technological Developments
   10.3. Merger & Acquisitions, and Joint Ventures
   10.4. Supply- Contract
11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   11.1. Bristol-Myers Squibb Company
   11.2. F. Hoffmann-La Roche Ltd.
   11.3. Merck & Co., Inc.
   11.4. Johnson & Johnson
   11.5. Abbott Laboratories, Inc.
   11.6. Affymetrix, Inc.
   11.7. AstraZeneca plc
   11.8. Bayer AG
   11.9. GE Healthcare
   11.10. GlaxoSmithKline plc
*More than 10 Companies are profiled in this Research Report*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix

   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Bibliography
   12.5. Compilation of Expert Insights
   12.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports